ClinicalTrials.gg
CompletedNCT02441894PEGAZUSUpdated Jan 24, 2017

Combination of Cabazitaxel With Prednisolone With Primary Prophylaxis With PEG-G-CSF in Treatment of Patients With Prostate Cancer

A Phase 4 interventional study of CABAZITAXEL XRP6258 and PEG-G-CSF in Prostate Cancer, sponsored by Sanofi. Completed at 8 sites in Japan. Open to male participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2017-01-24.

Sponsored by Sanofi · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
21
Allocation
Not applicable
Ages
20 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing prednisolone in Prostatic Neoplasms — 4 open to participants now, 5 under way, 2 of them phase 3. Prednisolone · Prostatic Neoplasms.

Enrollment
10th of 11
21 · median 218
Started
2015
the only one that year
Phase 4
2 of 11
none open now
Registered
7th of 11
by date
Lead sponsor
4 of 11
Sanofi

Among the 11 studies testing prednisolone in Prostatic Neoplasms, this one is the 10th largest by enrollment, is the only one that started in 2015, is one of 2 in phase 4, and was the 7th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

4 of the 11 studies testing prednisolone in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About prednisolone

Prednisolone: first FDA approval 1955 (METICORTELONE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 20 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing prednisolone in Prostatic Neoplasms, or all of them as a file.
02

Study summary

Primary Objective:

To assess the tolerability of cabazitaxel 25 mg per body surface area (m\^2) with primary prophylactic polyethylene glycol-granulocyte-colony stimulating factor (PEG-G-CSF) in terms of the incidence rate of febrile neutropenia (FN) (defined: absolute neutrophil count [ANC] \<1000 per volume [mm\^3] and a single temperature of >38.3 degree or a sustained temperature of ≥38 degree Celsius for more than one hour) during Cycle 1.

Secondary Objective:

To assess overall rate of FN and grade ≥3 neutropenia and diarrhea; frequencies of dose delay due to adverse events (AEs); dose reduction due to AEs; relative dose intensity; incidences of FN-related hospitalization and use of intravenous (IV) anti-infectives; tolerability according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v4.0; prostate specific antigen (PSA) response (50% decrease); tumor response according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 if available.

Read the detailed description

The total duration of study is 254 days as maximum with 14 days for screening, maximum of 21 days times 10 cycles for treatment, and 30 days for follow up.

03

Conditions studied

  • Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with castration-resistant prostate cancer (mCRPC) previously treated with chemotherapy including docetaxel.
  • Male patients.
  • Patients must have either measurable or nonmeasurable disease, or documented rising PSA levels.
  • Patients signed .

Exclusion criteria

Exclusion criteria:

  • Age \<20 at registration.
  • (ECOG) performance status (PS) ≥2.
  • Inadequate organ and bone marrow function at registration as evidenced by:

    • \<10.0 g/dL.
    • ANC \<5 x 10\^9/L.
    • count \<100 x 10\^9/L.
    • (AST) and/or alanine aminotransferase (ALT) >1.5 x (ULN).
    • Total >1.0 x ULN.
    • Serum creatinine >1.5 x ULN. Serum creatinine is 1.0-1.5 x ULN and is under 60 mL/min (calculated according to Chronic Kidney Disease Epidemiology Collaboration [CKD-EP]).
  • Prior isotope therapy or radiotherapy to ≥30% of bone marrow. At the first study drug administration day, patient has not elapsed 8 weeks (12 weeks for strontium-89) from the day prior isotope therapy finished.
  • Prior surgery, radiation, chemotherapy, or other anticancer therapy within 4 weeks prior to enrollment in the study.
  • Symptomatic peripheral neuropathy grade ≥2 ( v.4.0).
  • History of severe reaction (grade ≥3) to polysorbate 80 containing drugs.
  • Prior and other concurrent , excepted cases are as follows; basal cell carcinoma or squamous cell carcinoma of skin, or superficial (pTis, pTa, and pT1) bladder cancer (including immunotherapy) treated adequately, any other cancer completed the chemotherapy more than 5 years ago and been more than 5 years as disease free duration.
  • Uncontrolled severe illness or medical condition (including uncontrolled diabetes mellitus).
  • Known lesion at brain or leptomeninx.
  • Known acquired immunodeficiency syndrome (AIDS-related illnesses) or known (HIV) disease requiring antiretroviral treatment.
  • Active varicella zoster infection, anti- virus (HCV) antibody-positive (excluding patients negative for HCV virus in blood test or non-active seropositive patients with no hepatic abnormalities [AST, ALT, etc.]), or surface (HBs) antigen-positive.
  • Concurrent or planned treatment with strong inhibitors or strong inducers of cytochrome P450 3A4 or 5 ( for a one week is necessary for patients who are already on these treatments or a two-week wash-out period is necessary for patients who are already on these treatments).
  • to be used .
  • Patients with who do not agree to use an accepted and effective method of during the study treatment period. The definition of "effective method of contraception" will be based on the Investigator's judgment.
  • Participation in another clinical trial and any concurrent treatment with any drug within 30 days prior to registration.
  • Prior history of severe hypersensitivity reaction (≥grade 3) or intolerance to prednisolone, PEG-G-CSF or G-CSF.
  • Known hypersensitivity to the component of PEG-G-CSF and/or G-CSF.
  • Myelogenous leukemia insufficient decrease of the number of blast in bone marrow, or found myeloblast in peripheral blood.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Cabazitaxel

    25 mg/m\^2 of cabazitaxel is given intravenously in combination with prednisolone 10 mg orally per day. PEG-G-CSF is administered subcutaneously 24 hours after the completion of cabazitaxel infusion once every 3 weeks. Antihistamine (dexchlorpheniramine or diphenhydramine), corticosteroids (dexamethasone), and H2 antagonist (ranitidine) premedications will be administered by IV infusion at least 30 minutes prior to each dose of cabazitaxel. A prophylactic antiemetic treatment (metoclopramide, granisetron, or ondansetron) should be given to the patients in all cycles.

    Drug: CABAZITAXEL XRP6258 · Drug: PEG-G-CSF · Drug: Prednisolone · Drug: Dexchlorpheniramine or Diphenhydramine · Drug: Ranitidine · Drug: Metoclopramide, Granisetron, or Ondansetron · Drug: Dexamethasone

Interventions

  • Pharmaceutical form:solution Route of administration: intravenous

    Also known as: JEVTANA

  • Pharmaceutical form:solution Route of administration: subcutaneous

    Also known as: G-LASTA

  • Pharmaceutical form:tablet Route of administration: oral

  • DrugDexchlorpheniramine or Diphenhydramine

    Pharmaceutical form:tablet, powder, or solution Route of administration: oral, intravenous or intramuscular

  • Pharmaceutical form:tablet or solution Route of administration: oral, intravenous or intramuscular

  • DrugMetoclopramide, Granisetron, or Ondansetron

    Pharmaceutical form:tablet, powder, jelly, or solution Route of administration: oral, intravenous or intramuscular

  • Pharmaceutical form:tablet, capsule, or solution Route of administration: oral or intravenous

06

What researchers measure

Primary outcomes

  1. Number of patients with FN (all grades) during study Cycle 1

    Time frame: 3 weeks (during study Cycle 1)

Secondary outcomes

  1. Number of patients with FN (all grades)

    Time frame: Up to 7 months as treatment period

  2. Number of patients with Grade ≥3 neutropenia

    Time frame: Up to 7 months as treatment period

  3. Number of patients with Grade ≥3 diarrhea

    Time frame: Up to 7 months as treatment period

  4. Number of dose delays in the start of drug administration due to AEs

    Time frame: Up to 7 months as treatment period

  5. Number of dose reductions due to AEs

    Time frame: Up to 7 months as treatment period

  6. Percent change in relative dose intensity due to AEs

    Time frame: Up to 7 months as treatment period

  7. Number of patients with FN-related hospitalization

    Time frame: Up to 7 months as treatment period

  8. Number of patients who used IV anti-infective drugs

    Time frame: Up to 7 months as treatment period

  9. Changes of PSA levels from baseline

    Time frame: Up to 7 months as treatment period

  10. Number of patients with adverse events

    Time frame: Up to 7 months as treatment period

07

Study locations

8 sites
  • Investigational Site Number 392004
    Chuo-ku, Chiba, Japan
  • Investigational Site Number 392008
    Kita-gun, Japan
  • Investigational Site Number 392007
    Kobe-shi, Hyogo, Japan
  • Investigational Site Number 392005
    Nagakute-shi, Aichi, Japan
  • Investigational Site Number 392006
    Osaka Sayama-shi, Osaka, Japan
  • Investigational Site Number 392001
    Shinjuku-ku, Tokyo, Japan
  • Investigational Site Number 392002
    Yokohama-shi, Kanagawa, Japan
  • Investigational Site Number 392009
    Yokohama-shi, Japan
08

References and documents

Publications

  • Kosaka T, Uemura H, Sumitomo M, Harada K, Sugimoto M, Hayashi N, Yoshimura K, Fukasawa S, Ecstein-Fraisse E, Sunaga Y, Oya M. Impact of pegfilgrastim as primary prophylaxis for metastatic castration-resistant prostate cancer patients undergoing cabazitaxel treatment: an open-label study in Japan. Jpn J Clin Oncol. 2019 Aug 1;49(8):766-771. doi: 10.1093/jjco/hyz051. PubMed 31329922 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2015, a primary completion of Feb 2016 and a completion of Nov 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2015
First posted
May 12, 2015
Start
Apr 2015
Primary completionActual
Feb 2016
CompletionActual
Nov 2016
Last update
Jan 24, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02441894
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
May 12, 2015
Start date
Apr 2015
Primary completion
Feb 2016
Completion
Nov 2016
Last update
Jan 24, 2017

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Prednisolone

Start the discussion